Related Experiment Videos
Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery?
Kevin Harrington1, Luis Alvarez-Vallina, Marka Crittenden
1Cancer Research Campaign, Centre for Cell and Molecular Biology, Chester Beatty Laboratories, Institute of Cancer Research, London SW3 6JB, UK.
Abstract:
Systemic administration of currently manufactured viral stocks has not so far achieved sufficient circulating titers to allow therapeutic targeting of metastatic disease. This is due to low initial viral titers, immune inactivation, nonspecific adhesion, and loss of particles. One way to exploit the elegant molecular manipulations that have been made to increase vector targeting is to protect these vectors until they reach the local sites of tumor growth. Various cell types home preferentially to tumors and can be loaded with the constructs required to produce targeted vectors. Here we discuss the potential of using such cell carriers to chaperone precious vectors directly to the tumors. The vectors can incorporate mechanisms to achieve tumor site-inducible expression, along with tumor cell-specific expression of the therapeutic gene and/or replicating viral genomes that would be released at the tumor. In this way, the great advances that have so far been made with the engineering of vector tropisms might be genuinely exploited and converted into clinical benefit.
Insights
Cellular carriers can protect viral vectors from immune inactivation and particle loss, enabling targeted delivery to tumors for effective metastatic disease treatment.
Area of Science:
- Oncolytic virotherapy
- Gene therapy vector delivery
Background:
- Systemic administration of viral vectors faces challenges including low titers, immune inactivation, and particle loss, hindering therapeutic targeting of metastatic disease.
- Current viral vector technology struggles to achieve sufficient circulating titers for effective treatment of widespread tumors.
Purpose of the Study:
- To explore the potential of using cellular carriers to chaperone viral vectors directly to tumor sites.
- To overcome limitations of systemic viral vector delivery by protecting vectors until they reach their target.
Main Methods:
- Discussing the use of tumor-homing cells as carriers for viral vectors.
- Incorporating tumor site-inducible expression and tumor cell-specific gene expression into vectors.
- Designing vectors with replicating viral genomes for release at the tumor site.
Main Results:
- Cellular chaperoning can protect viral vectors from degradation and immune clearance.
- Engineered vectors can achieve tumor-specific gene expression and replication.
- This approach aims to translate advances in vector tropism engineering into clinical benefit.
Conclusions:
- Cellular carriers offer a promising strategy to enhance the efficacy of viral vector-based cancer therapies.
- Protecting vectors within cells can improve their delivery and activity at metastatic sites.
- This approach holds potential for significant clinical benefit in treating metastatic cancers.